The document provides an overview of Veru Inc.'s product development pipeline, financial highlights, and market opportunities. It includes information on prostate cancer novel medicines, urology specialty pharmaceuticals, and the FC2 Female Condom business. Key products in development include Zuclomiphene and VERU-111 for prostate cancer, and Tamsulosin XR, Tadalafil-finasteride combo, and Solifenacin DRG for urology. Financial highlights include net revenues, gross profit, and operating loss for the nine months ended June 30, 2018, and the year ended September 30, 2017.
documents/EFTA00810552.pdf
{}